...
【24h】

Intravascular stents in the last and the next 10 years.

机译:最近十年和未来十年的血管内支架。

获取原文
获取原文并翻译 | 示例

摘要

The first balloon-expandable coronary stent was approved "for the prevention of restenosis" in 1994, the same year that the Journal of Endovascular Therapy was inaugurated. Since then, the development of the stent has paralleled the evolution of endovascular intervention as a new specialty. Innovators have pushed to explore new and varied stent applications outside the coronary arteries. Carotid stenting, transjugular intrahepatic portocaval shunts, and covered stents are a few of these new applications that have now become commonplace. Dozens of stent designs and several new materials have been tested to solve the problem of in-stent restenosis, but it is the drug-eluting stent (DES) that has emerged as the most promising, at least in the coronary arteries. However, the benefits of DES technology are not likely to be effective in the more pervasive forms of in-stent restenosis, such as encountered in the femoropopliteal segment.In the future, technologies aimed at stimulating rather than inhibiting tissue response to an implant may be part of the next wave of developments, as we take aim against the poor and/or slow tissue incorporation that manifests as leaks and dislodgement. In the superficial femoral artery, for example, mechanical stresses that cause fractures and dislocations may be addressed by using a very flexible endovascular device with a tissue-friendly inner surface that promotes rapid stent endothelialization to counter the biological effects of motion and microtrauma. The rapidly developing fields of nanotechnology, microelectronics, and advanced materials technology will enable the surface engineer to design molecular-specific surfaces for a new generation of vascular devices. Interactive implantable or injectable microdevices aimed at providing specific information upon demand from an external source will revolutionize disease prevention, as emphasis shifts toward monitoring cardiovascular risk exposure. There is no doubt that during the next 10 years, we will witness impressive technological progress in the field of cardiovascular implantable devices.
机译:1994年,即《血管内治疗杂志》(Journal of Endovascular Therapy)揭幕的同一年,首个气囊扩张式冠状动脉支架被批准用于“预防再狭窄”。从那时起,支架的发展已与血管内介入的发展平行,成为一种新的专业。创新者已推动探索冠状动脉以外的新型支架应用。颈动脉支架置入术,经颈静脉肝内门静脉分流术和覆膜支架术是如今已变得司空见惯的一些新应用。为了解决支架内再狭窄的问题,已经测试了数十种支架设计和几种新材料,但是药物洗脱支架(DES)至少在冠状动脉中已成为最有前途的。然而,DES技术的好处在股骨lite段等更普遍的支架内再狭窄形式中不太可能有效。将来,旨在刺激而不是抑制组织对植入物反应的技术可能会成为现实。是下一波发展浪潮的一部分,因为我们着眼于针对表现为渗漏和移位的不良和/或缓慢的组织合并。例如,在股浅动脉中,可通过使用具有组织友好内表面的非常灵活的血管内装置来解决引起骨折和脱位的机械应力,该装置可促进快速支架内皮化以抵消运动和微创伤的生物学效应。纳米技术,微电子学和先进材料技术的快速发展领域将使表面工程师能够为新一代血管装置设计分子特异性表面。交互式可植入或可注射微型设备旨在根据外部需求提供特定信息,这将彻底改变疾病预防,因为重点已转向监控心血管风险暴露。毫无疑问,在接下来的十年中,我们将见证心血管植入设备领域的令人瞩目的技术进步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号